BIOGAIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 115.2 SEK | +1.23% |
|
-3.60% | +13.83% |
| Apr. 03 | Nordic Shares Rose Wednesday; BW LPG Led Increases | DJ |
| Mar. 28 | Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 28.87 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.83% | 1.06B | B- | ||
| -4.66% | 86.13B | A- | ||
| +1.32% | 39.82B | A- | ||
| -19.27% | 30.42B | B- | ||
| +57.86% | 25.23B | A | ||
| -16.09% | 15.35B | C | ||
| -9.14% | 11.95B | D+ | ||
| -17.69% | 11.6B | B- | ||
| -43.00% | 11.51B | B | ||
| +5.24% | 8.71B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOG B Stock
- Ratings BioGaia AB
